Gene Therapy Company, Affinia Therapeutics, Appoints Carole Faig to its Board of Directors

Chartwell is pleased to have partnered with Affinia Therapeutics to recruit Carole Faig to the Board of Directors. Affinia Therapeutics is an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) gene therapies for rare and prevalent devastating diseases. Carole recently retired from Ernst & Young (EY) after almost 40 years of audit and public accounting experience. Most recently, she served as a leader of EY’s U.S. healthcare business, where she was responsible for developing and driving the firm’s strategy to grow its healthcare practice during a period of rapid change in the health industry. Additionally, Ms. Faig served as an audit partner for a wide range of companies in the healthcare industry, from large and complex health systems to private equity backed growth companies and SEC registrants. In that role, she assisted companies with public equity offerings, working closely with investment bankers, underwriters, and legal counsel, and advised clients on financial accounting and reporting matters.